Editas Medicine Inc

8EM

Company Profile

  • Business description

    Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

  • Contact

    11 Hurley Street
    CambridgeMA02141
    USA

    T: +1 617 401-9000

    E: [email protected]

    https://www.editasmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    226

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,831.5053.600.61%
CAC 407,878.46111.751.44%
DAX 4024,549.56342.651.42%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,867.0212.840.15%
HKSE23,914.7922.470.09%
NASDAQ20,611.34192.870.94%
Nikkei 22539,616.80204.48-0.51%
NZX 50 Index12,736.6931.92-0.25%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,593.7055.100.65%
SSE Composite Index3,505.5812.530.36%

Market Movers